Headlines about aTyr Pharma (NASDAQ:LIFE) have been trending positive on Friday, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. aTyr Pharma earned a news sentiment score of 0.35 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.3285639356122 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have effected Accern’s analysis:
- William Blair Analysts Lift Earnings Estimates for aTyr Pharma, Inc. (LIFE) (americanbankingnews.com)
- ATYR PHARMA, INC. (NASDAQ:LIFE) Files An 8-K Results of Operations and Financial Condition (4-traders.com)
- aTyr Pharma, Inc. (LIFE) Releases Earnings Results, Beats Estimates By $0.06 EPS (americanbankingnews.com)
- aTyr Pharma, Inc. (LIFE) Given “Hold” Rating at BMO Capital Markets (americanbankingnews.com)
- Atyr Pharma : reports 2Q loss (4-traders.com)
Shares of aTyr Pharma (NASDAQ:LIFE) traded down 3.70% during trading on Friday, hitting $2.60. 28,441 shares of the company’s stock were exchanged. aTyr Pharma has a 1-year low of $2.10 and a 1-year high of $4.45. The firm’s market capitalization is $61.98 million. The stock’s 50 day moving average is $3.29 and its 200 day moving average is $3.37.
aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.06. On average, equities research analysts forecast that aTyr Pharma will post ($2.18) earnings per share for the current year.
LIFE has been the topic of a number of analyst reports. BMO Capital Markets restated a “hold” rating on shares of aTyr Pharma in a research report on Wednesday, May 24th. ValuEngine upgraded shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, July 8th. Finally, Zacks Investment Research upgraded shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a research report on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. aTyr Pharma has a consensus rating of “Hold” and a consensus target price of $3.65.
ILLEGAL ACTIVITY NOTICE: “Favorable Media Coverage Somewhat Unlikely to Affect aTyr Pharma (NASDAQ:LIFE) Share Price” was published by BBNS and is the property of of BBNS. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://baseballnewssource.com/markets/favorable-news-coverage-somewhat-unlikely-to-affect-atyr-pharma-nasdaqlife-share-price-updated/1408460.html.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with our FREE daily email newsletter.